We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development

News   Nov 02, 2005

 
Max Planck Institute and Cellomics Announce Collaboration for High Content Screening Development
 
 
Advertisement
 

RELATED ARTICLES

Study Investigates Racial Disparities in Clinical Trial Recruitment

News

Scientists are increasingly turning to electronic-based recruitment methods to encourage participation in clinical trials. Little is known about how this use of technology compares to more traditional clinical trial recruitment strategies, and some researchers worry that an overreliance on technology has the potential to exclude an eligible and interested diverse participant population.

READ MORE

CD19 in Brain Cells May Be Cause of Immunotherapy-Related Neurotoxicity

News

New research has uncovered the presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB).

READ MORE

Team Identifies Potential Pitfall in Emerging Treatment for Cancer and Inflammation

News

Whilst studying an emerging drug target in cancer and inflammation, researchers discovered the unintended activation of a protein called ERK5, this activation was due to the binding location of the inhibitors. ERK5 inhibitors that bound to the kinase domain of the protein led to the protein being shuttled to the cell nucleus and activated. Blocking ERK5 has therapeutic potential, but activating it could have undesirable consequences in terms of stimulated unwanted cell growth.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE